Tryptamine-Functionalized Lipid Nanocarriers Co-delivering SMO/BRD4 Inhibitors for Synergistic Medulloblastoma...

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Medulloblastoma (MB) management is challenging due to cancer stem cells and poor drug delivery across the blood-brain barrier.
• GLI proteins regulate hedgehog signaling and are crucial in MB initiation, progression, metastasis, and stem cell maintenance.

Purpose of the Study:

• To develop a combined therapeutic strategy using BRD4 inhibitor JQ1 and SMO inhibitor saikosaponin B1 (SSB1) to target GLI activation in MB.
• To utilize tryptamine-derived lipid nanoparticles (NPs) for targeted delivery of JQ1 and SSB1 to MB tissues.

Main Methods:

• Synergistic inhibition of MB proliferation and metastasis by combining JQ1 and SSB1.
• Down-regulation of stem cell phenotypes through reduced GLI and MYC expression.
• Development and evaluation of targeted lipid nanoparticles for drug delivery to MB tumors.

Main Results:

• JQ1 and SSB1 demonstrated synergistic effects in inhibiting MB proliferation and metastasis.
• Combined treatment reduced MB stem cell phenotypes by decreasing GLI and MYC expression.
• Targeted NPs enhanced drug accumulation in MB tumors and reduced tumor burden in mice without hepatic toxicity.

Conclusions:

• The combination of JQ1 and SSB1 offers a promising therapeutic approach for medulloblastoma.
• Targeted nanoparticle delivery improves drug efficacy and reduces systemic toxicity for MB treatment.
• This strategy has the potential to advance novel treatment strategies for medulloblastoma suppression, recurrence, and metastasis.